Ameera Jailani

Dr. Ameera Jailani

University of Sheffield, Sheffield, UK
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
PAParis Avgoustou
Paris Avgoustou
Ameera JailaniAmeera Jailani
Ameera Jailani
JZJean-Olivier Zirimwabagabo
Jean-Olivier Zirimwabagabo
MTMatthew J. Tozer
Matthew J. Tozer
KGKarl R. Gibson
Karl R. Gibson
GRGareth Owain Richards
Gareth Owain Richards

22 June 2022 in Expert Opinion on Drug Discovery
Verified
Journal Article
Open access
Ameera JailaniAmeera Jailani
Ameera Jailani
KBKamilla J. A. Bigos
Kamilla J. A. Bigos
PAParis Avgoustou
Paris Avgoustou
JEJoseph L. Egan
Joseph L. Egan
RHRobert A. Hathway
Robert A. Hathway
GRGareth Owain Richards
Gareth Owain Richards
Adrenomedullin (AM) is a peptide responsible for many physiological processes including vascular health and hormone regulation. Dysregulation of AM signaling can stimulate cancers by promoting prol...

21 October 2022 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
AKAmy Kwan
Amy Kwan
FHFaith Howard
Faith Howard
NWNatalie Jayne Winder
Natalie Jayne Winder
EAEmer Atkinson
Emer Atkinson
Ameera JailaniAmeera Jailani
Ameera Jailani
Munitta MuthanaMunitta Muthana
Munitta Muthana
Oncolytic viruses (OV) promote anti-tumour responses through the initiation of immunogenic cancer cell death which activates the host’s systemic anti-tumour immunity. We have previously shown that intravenously administered HSV1716 is an effective treatment for mammary cancer. However, intravenous administration of a virus has the potential to result in neutralization and sequestration of the virus which may reduce efficacy. Here, we show that the oncolytic virus HSV1716 can be administered within a cellular carrier (macrophages). PyMT and 4T1 murine mammary cancer cell lines were implanted into immuno-competent murine models (orthotopic primary, early metastatic and brain metastasis models). HSV1716 or macrophages armed with HSV1716 (M-HSV1716) were administered intravenously, and tumour size was quantified using caliper measurement or bioluminescence imaging. Administration of M-HSV1716 led to tumour shrinkage and increased the survival of animals. Furthermore, these results were achieved with a 100-fold lower viral load, which has the potential for decreased toxicity. Our results demonstrate that M-HSV1716 is associated with activity against murine mammary cancers and provides an alternative platform for the systemic delivery of OV.

5 March 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JZJean-Olivier Zirimwabagabo
Jean-Olivier Zirimwabagabo
Ameera JailaniAmeera Jailani
Ameera Jailani
PAParis Avgoustou
Paris Avgoustou
MTMatthew J. Tozer
Matthew J. Tozer
KGKarl R. Gibson
Karl R. Gibson
JHJoe Harrity
Joe Harrity
Class B G-protein-coupled receptors (GPCRs) remain an underexploited target for drug development. The calcitonin receptor (CTR) family is particularly challenging, as its receptors are heteromers comprising two distinct components: the calcitonin receptor-like receptor (CLR) or calcitonin receptor (CTR) together with one of three accessory proteins known as receptor activity-modifying proteins (RAMPs). CLR/RAMP1 forms a CGRP receptor, CLR/RAMP2 forms an adrenomedullin-1 (AM1) receptor, and CLR/RAMP3 forms an adrenomedullin-2 (AM2) receptor. The CTR/RAMP complexes form three distinct amylin receptors. While the selective blockade of AM2 receptors would be therapeutically valuable, inhibition of AM1 receptors would cause clinically unacceptable increased blood pressure. We report here a systematic study of structure–activity relationships that has led to the development of first-in-class AM2 receptor antagonists. These compounds exhibit therapeutically valuable properties with 1000-fold selectivity over the AM1 receptor. These results highlight the therapeutic potential of AM2 antagonists.

19 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
PAParis Avgoustou
Paris Avgoustou
Ameera JailaniAmeera Jailani
Ameera Jailani
ADAditya J. Desai
Aditya J. Desai
DRDave J. Roberts
Dave J. Roberts
ELEwan R. Lilley
Ewan R. Lilley
GRGareth Owain Richards
Gareth Owain Richards
Receptor activity-modifying proteins (RAMPs) are known to modulate the pharmacology and function of several G protein-coupled receptors (GPCRs), including the parathyroid hormone 1 receptor (PTH1R). However, the precise effects of different RAMPs on PTH1R signalling and trafficking remain poorly understood. Here we investigated the impact of RAMP2 and RAMP3 on PTH1R function using a range of PTHand PTH-related protein (PTHrP)-derived ligands. FRET imaging revealed that PTH1R preferentially interacts with RAMP2 and, to a lesser extent, RAMP3, but not RAMP1. Interestingly, RAMP3 co-expression resulted in reduced cell surface expression of PTH1R, suggesting a potential role in receptor trafficking or internalization. The presence of RAMP2 significantly enhanced PTH1R-mediated cAMP accumulation, β-arrestin recruitment, and calcium signalling in response to PTH (1–34), PTHrP (1-34), PTH (1-84), and the PTH (1-17) analogue ZP2307. In contrast, RAMP3 co-expression attenuated or completely abolished those responses. We found that full-length PTHrP analogues, PTHrP (1-108) and PTHrP (1-141), exhibited lower potency and efficacy than PTHrP (1-34) in activating PTH1R. RAMP2 significantly increased potency and/or efficacy when compared to PTH1R alone cells, while RAMP3 significantly reduced these responses. Antibody-capture scintillation proximity assays demonstrated that RAMP2 differentially modulates G protein activation by PTH1R in a ligand-dependent manner, with PTH (1-34) and PTHrP (1-34) inducing distinct patterns of G protein subtype activation. These findings highlight the complex role of RAMPs in regulating PTH1R signalling and trafficking, revealing differential effects of RAMP2 and RAMP3 on receptor function. The data suggest that targeting the PTH1R/RAMP2 complex may be a promising strategy for developing novel bone anabolic therapies by leveraging biased agonism and functional selectivity. Further research using physiologically relevant models is needed to elucidate the therapeutic potential of this approach.